New ATMP guidance: T Cell and NK Cell Characterisation Assays
Date published: 8 April 2024
With complexity and risk associated with each stage of assay development, our Advanced Therapy Medicinal Products (ATMP) T Cell and NK Cell Characterisation Assays best practice guidance offers a practical and phase appropriate validation tool to help your cell therapy programme succeed.
This new guidance, the fourth the British Pharmacopoeia (BP) has produced, was developed and approved by the BP, as part of the MHRA, in partnership with experts from the cell and gene therapy community including industry, the NHS and academia.
Available as part of the BP online and free to download, our new ATMP guidance supports the ATMP community to standardise operations and feel confident to do their job more effectively.